Tirzepatide (Mounjaro / Zepbound)
A dual incretin agonist that activates both GIP and GLP-1 receptors, producing the largest weight loss of any approved pharmacotherapy to date. SURMOUNT-1 demonstrated up to 22.5% body-weight reduction at 72 weeks on the 15mg dose — outperforming semaglutide head-to-head. The added GIP component improves insulin sensitivity and may partially offset the muscle loss seen with GLP-1 monotherapy.
Reviewed & fact-checked by
BiohackingHub Research TeamEditorial Research Team · Last updated: May 11, 2026
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
Stacking Interactions
How Tirzepatide (Mounjaro / Zepbound) interacts with other compounds
Creatine supports strength and lean-mass retention during the rapid weight loss tirzepatide drives — a cornerstone of muscle-preservation protocols.
Used as an off-cycle metabolic bridge to maintain glycaemic control and blunt weight regain after tapering tirzepatide.
Both are incretin agonists — do not combine. Tirzepatide is typically used instead of, not alongside, semaglutide.
Pairs in longevity-oriented metabolic protocols; reduced insulin signalling from tirzepatide complements NAD+-driven mitochondrial support.
Protocols using Tirzepatide (Mounjaro / Zepbound)
Evidence-graded stacks that include this compound
Safety Profile — Tier B
Generally safe — moderate evidence
Contraindications
- ●Personal or family history of medullary thyroid carcinoma (MTC)
- ●Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- ●History of pancreatitis
- ●Pregnancy and breastfeeding
- ●Severe gastrointestinal disease or gastroparesis
Side Effects
- ●Nausea — common, especially during titration (dose-dependent)
- ●Diarrhoea and vomiting
- ●Constipation
- ●Reduced appetite (intended effect)
- ●Fatigue and lean-mass loss during rapid weight loss
- ●Rare: pancreatitis, gallbladder disease